Program
SRC/YES1 Kinase Inhibitor NXP900
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Nuvectis Pharma.
Furthest: phase 1, since May 15, 20233 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nuvectis Pharma | 33 open or running | phase 1since May 15, 2023 | May 15, 2023 | Dec 2026phase 1 · NCT07315113 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05873686 · 140 enrolled · United States, United Kingdom
- Dec 18, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07315113 · 18 planned · United States
- Aug 20, 2026Phase 1 study in ALK PositiveNCT07784959 · 54 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07315113
- Mar 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05873686
- Aug 2027Primary completion: phase 1 study in ALK PositiveNCT07784959
TargetBeta
“An orally bioavailable inhibitor of SRC family of kinases (SFK), including SRC and YES1, ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07784959ALK Positive · United States | 1 | Recruiting | Aug 2027 | 54 |
| NCT07315113Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Dec 2026 | 18 |
| NCT05873686Carcinoma, Non-Small-Cell Lung · United States, United Kingdom | 1 | Active, not recruiting | Mar 2027 | 140 |
How it is read
Names in the registry
- “NXP900”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.